The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an<a href="https://solaci.org/en/2015/06/24/bright-bivalirudin-versus-heparin-versus-heparin-plus-tirofiban-in-primary-angioplasty/" title="Read more" >...</a>

There are clinics hypothesis that systemic hypothermia (&le;34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and given the large surface area of the bowel may cause rapid hypothermia reducing infarct size. The aim of this study was to evaluate the safety and efficacy of hypothermia induced by<a href="https://solaci.org/en/2015/06/24/velocity-peritoneal-hypothermia-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

This study included 201 patients suffering ST-segment elevation acute coronary syndrome and randomized to the use of optical coherence tomography (OCT) versus conventional angiography for the procedure. OCT-guided group used more stents per patient (1.4 versus 1.2, p = 0.03) and greater release pressure. During control OCT suboptimal results were found in a third of<a href="https://solaci.org/en/2015/06/24/oct-stemi-primary-angioplasty-guided-by-oct/" title="Read more" >...</a>

The aim of this study was to evaluate the modification in residual platelet reactivity by adjusting the prasugrel dose from 10 mg to 5 mg after the acute phase (1 month) of ACS. 450 patients were included receiving a loading dose of 60 mg followed by a month of 10 mg of prasugrel and randomized<a href="https://solaci.org/en/2015/06/24/bless-assessment-of-platelet-reactivity-in-patients-undergoing-angioplasty-receiving-prasugrel/" title="Read more" >...</a>

This work aimed to evaluate the use of optical coherence tomography (OCT) to guide the drug-eluting stent implantation during primary angioplasty. 201 patients experiencing STEMI to use or not OCT during primary angioplasty were randomized. The clinical and angiographic characteristics were well balanced, and no differences in MACE, cardiac death, TLR, or stent thrombosis at<a href="https://solaci.org/en/2015/06/24/robust-routinely-use-of-oct-in-primary-angioplasty-with-des-showed-no-benefit/" title="Read more" >...</a>

There are experimental studies suggesting that metformin admin before and during ischemia and reperfusion could help to preserve left ventricular function regardless of glycometabolic state.In observational studies, the concomitant use of metformin is associated with a lower peak CK MB and troponin.380 nondiabetic patients undergoing primary angioplasty for acute coronary syndrome study with ST segment<a href="https://solaci.org/en/2015/06/24/gips-iii-metformin-does-not-improve-ejection-fraction-in-non-diabetic-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

Atherosclerotic stenosis of the renal artery is common in the elderly population. Previous clinical trials showed no benefit with angioplasty in relation to renal function but their use for preventing cardiovascular events was still uncertain. A total of 947 patients with atherosclerotic renal artery and systolic hypertension (need two or more drugs) or renal dysfunction<a href="https://solaci.org/en/2015/06/24/coral-angioplasty-versus-medical-treatment-of-renal-artery-stenosis/" title="Read more" >...</a>

The STREAM study (Strategic Reperfusion Early After Myocardial Infarction) that included 1891 patients gave support to the fibrinolytic infusion strategy in the ambulance in patients treated within 3 hours of stroke and who cannot receive primary angioplasty within the hour versus primary angioplasty. The primary end point was a composite of death from any cause,<a href="https://solaci.org/en/2015/06/24/stream-trial-pharmacological-invasive-strategy-versus-primary-angioplasty/" title="Read more" >...</a>

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological and non-pharmacological agents administered before or during the ischemic period could significantly reduce infarct size in experimental studies in humans, but the results were inconsistent. This study tested the hypothesis that intravenous nitroprusside infusion immediately before the opening<a href="https://solaci.org/en/2015/06/24/niami-nitroprusside-infusion-prior-to-primary-angioplasty/" title="Read more" >...</a>

ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in patients undergoing elective angioplasty. All patients received a rosuvastatin dose of 40 mg (GR) or atorvastatin 80 mg (GA) within 24 hours of the procedure. The primary endpoint of the study<a href="https://solaci.org/en/2015/06/24/roma-ii-reload-additional-charge-of-statin-rosuvastatin-40-mg-or-atorvastatin-80-mg-within-24-hours-of-procedure-in-patients-on-whom-elective-angioplasty-is-performed/" title="Read more" >...</a>